NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its second quarter revenues rose 4 percent, driven in part by strong growth in automated sample-to-answer molecular products sales.

For the three months ended June 30, the firm reported revenues of $79.6 million, up from $76.5 million a year ago, and in line with the consensus Wall Street estimate.